Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study We conducted a multicenter, open-label, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results